Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Polypill versus usual care for secondary prevention after acute myocardial infarction
IRCT20180507039571N2Phase 3Completed
- Sponsor
- NIMAD
- Start
- May 2019
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of aspirin, atorvastatin, metoprolol and valsartan in myocardial infarction (MI) and cardiac morbidity (2 arms), sponsored by NIMAD. Primary endpoint: Major adverse cardiovascular events composite. Started May 2019; status: completed.
02
Drugs
aspirinatorvastatinmetoprololvalsartan
03
Conditions
myocardial infarction (MI)cardiac morbidity
Beyond the preview
Go deeper on IRCT20180507039571N2.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20180507039571N2.